– Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. – Biologics License Application (BLA) submission for accelerated approval is supported by […]
